Indirect Comparison of Adverse Events and Dropout Rates for Early Parkinson's Disease (PD) Monotherapy Trials: Pramipexole, Ropinirole, and Rasagiline

被引：0
|
作者：
Tarrants, M. T.
Zagmutt, F. J.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S724 / S725
页数：2
相关论文
共 50 条
  • [41] A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
    Singer, Carlos
    Lamb, Janice
    Ellis, Amanda
    Layton, Gary
    MOVEMENT DISORDERS, 2007, 22 (04) : 476 - 482
  • [42] Low incidence of cognitive and behavioral adverse events in rasagilinetreated patients with early to advanced Parkinson's disease (PD).
    Chen, JJ
    Berchou, RC
    PHARMACOTHERAPY, 2005, 25 (10): : 1466 - 1466
  • [43] Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting: An Economic Markov Model Evaluation
    Kovacs, Norbert
    Janszky, Jozsef
    Nagy, Ferenc
    DRUGS & AGING, 2011, 28 (02) : 161 - 162
  • [44] Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease
    Solis-Garcia del Pozo, Julian
    Minguez-Minguez, Sara
    de Groot, Piet W. J.
    Jordan, Joaquin
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (04) : 479 - 486
  • [45] Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK SettingAn Economic Markov Model Evaluation
    Alan Haycox
    Christophe Armand
    Susana Murteira
    John Cochran
    Clément François
    Drugs & Aging, 2009, 26 : 791 - 801
  • [46] Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK SettingAn Economic Markov Model Evaluation
    Norbert Kovacs
    Jozsef Janszky
    Ferenc Nagy
    Drugs & Aging, 2011, 28 : 161 - 162
  • [47] Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting An Economic Markov Model Evaluation
    Haycox, Alan
    Armand, Christophe
    Murteira, Susana
    Cochran, John
    Francois, Clement
    DRUGS & AGING, 2009, 26 (09) : 791 - 801
  • [48] Four year safety and adverse events in an open label experience of 306 patients on pramipexole for Parkinson's disease
    Factor, SA
    Weiner, WJ
    Jankovic, J
    Hauser, RA
    Tetrud, JW
    Waters, CH
    Shulman, LM
    Glassman, PM
    Beck, B
    Paume, D
    Doyle, C
    NEUROLOGY, 1999, 52 (06) : A407 - A408
  • [49] A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson's disease (PD)
    Tan, Y.
    Wei, Q.
    Xu, P.
    Tao, E.
    Wang, L.
    Cattaneo, C.
    Shang, H.
    Chen, S.
    MOVEMENT DISORDERS, 2024, 39 : S318 - S319
  • [50] Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson's disease patients with a matching adjusted indirect comparison
    Tan, Yuyan
    Wei, Qianqian
    Xu, Pingyi
    Tao, Enxiang
    Wang, Lijiao
    Cattaneo, Carlo
    Shang, Huifang
    Chen, Shengdi
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345